Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street
Abivax Crashes Most On Record After Cancer Cases In Trial Data Spooks Wall Street French biotech Abivax suffered its largest intraday decline on record after reporting new data on its lead experimental inflammatory bowel disease drug, which showed cancer cases among patients in the clinical trial. The new data certainly point to regulatory headwinds and raise the risk profile for approval. Abivax's ABTECT maintenance data showed strong efficacy readout, with both once-daily obefazi...
Original Source
Read the full article at Zerohedge →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.